Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19532631 | 1.00 | EPHX1 (0.62) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL1715476 | 0.97 | EPHX1 (0.58) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5485166 | 0.92 | — | — | |
| SCHEMBL2465665 | 0.87 | — | — | |
| SCHEMBL22081717 | 0.78 | EPHX1 (0.38) | EPHX1DPP4 | |
| SCHEMBL22081716 | 0.78 | EPHX1 (0.38) | EPHX1DPP4 | |
| SCHEMBL22081098 | 0.78 | EPHX1 (0.38) | EPHX1DPP4 | |
| SCHEMBL22081715 | 0.78 | EPHX1 (0.38) | EPHX1DPP4 | |
| SCHEMBL67018 | 0.77 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA | |
| SCHEMBL5686769 | 0.77 | EPHX1 (0.46) | EPHX1TP53KDM4EGMNNLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299377-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002000641-A2 | SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9745304-B2 | Amidoimidazopyridazines as MKNK-1 kinase inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20150376189-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-31 | — | — | US | disclosed |
| EP-2951181-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014118135-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| EP-2582705-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| WO-2011161009-A1 | ANELLATED PYRIDINE COMPOUNDS AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-29 | — | — | WO | disclosed |
| US-6743794-B2 | MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE | ELI LILLY AND COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-6207852-B1 | THERAPY FOR INCONTINENCE; CROHN'S DISEASE; MUSCLE RELAXANTS | BRIDGE PHARMA, INC. | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376189-A1 | AMIDOIMIDAZOPYRIDAZINES AS MKNK-1 KINASE INHIBITORS | MKNK1, MAP4K5, MAP3K1 | EPHX1 2339/4885TP53 1870/4885KDM4E 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.